Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 780

1.

Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.

Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM.

Am J Ophthalmol. 2007 Apr;143(4):601-6.

PMID:
17306753
2.

Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.

Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1635-41. doi: 10.1007/s00417-009-1151-1.

PMID:
19633982
3.

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.

Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF.

Retina. 2006 Mar;26(3):279-84.

PMID:
16508427
4.

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.

Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL.

Retina. 2007 Apr-May;27(4):419-25.

PMID:
17420692
5.

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.

Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH; Retinal Vein Occlusion Study Group..

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):183-92. doi: 10.1007/s00417-010-1470-2.

6.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
7.

Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema.

Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK.

Doc Ophthalmol. 2008 Mar;116(2):129-35.

PMID:
17960440
8.

Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.

Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J; Pan-American Collaborative Retina Study Group (PACORES)..

Retina. 2008 Feb;28(2):212-9. doi: 10.1097/IAE.0b013e3181619bee.

PMID:
18301025
9.

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.

Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U.

Br J Ophthalmol. 2009 Apr;93(4):452-6. doi: 10.1136/bjo.2008.141085.

PMID:
19074916
10.

Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.

Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU.

Retina. 2007 Feb;27(2):141-9.

PMID:
17290194
11.

Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.

Loukianou E, Brouzas D, Chatzistefanou K, Koutsandrea C.

Int Ophthalmol. 2016 Feb;36(1):21-36. doi: 10.1007/s10792-015-0066-6.

PMID:
25820576
12.

Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.

Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A.

Retina. 2007 Oct;27(8):1004-12.

PMID:
18040236
13.

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A.

Retina. 2006 Nov-Dec;26(9):999-1005.

PMID:
17151486
14.

Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.

Rouvas A, Petrou P, Ntouraki A, Douvali M, Ladas I, Vergados I.

Retina. 2010 Jun;30(6):893-902. doi: 10.1097/IAE.0b013e3181cd4894.

PMID:
20531142
15.

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.

Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C.

Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48.

PMID:
18779710
16.

Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C.

Eur J Ophthalmol. 2012 Jul-Aug;22(4):607-14. doi: 10.5301/ejo.5000085.

PMID:
22101497
17.

Results of bevacizumab as the primary treatment for retinal vein occlusions.

Figueroa MS, Contreras I, Noval S, Arruabarrena C.

Br J Ophthalmol. 2010 Aug;94(8):1052-6. doi: 10.1136/bjo.2009.173732.

PMID:
20679089
18.

Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.

Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U.

Br J Ophthalmol. 2008 Apr;92(4):518-22. doi: 10.1136/bjo.2007.127282.

PMID:
18211942
19.

Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.

Puche N, Glacet A, Mimoun G, Zourdani A, Coscas G, Soubrane G.

Acta Ophthalmol. 2012 Jun;90(4):357-61. doi: 10.1111/j.1755-3768.2010.01913.x.

20.

Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.

Yamaike N, Tsujikawa A, Sakamoto A, Ota M, Kotera Y, Miyamoto K, Kita M, Yoshimura N.

Retina. 2009 Jun;29(6):757-67. doi: 10.1097/IAE.0b013e31819d4fbf.

PMID:
19289982

Supplemental Content

Support Center